OTCMKTS:INNV - Innovus Pharmaceuticals Stock Price, Forecast & News

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

Innovus Pharmaceuticals Inc (OTCMKTS:INNV) released its earnings results on Tuesday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company earned $7.31 million during the quarter. Innovus Pharmaceuticals had a negative net margin of 35.85% and a negative return on equity of 1,611.96%. View Innovus Pharmaceuticals' Earnings History.

Innovus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Innovus Pharmaceuticals.

1 brokers have issued twelve-month target prices for Innovus Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Innovus Pharmaceuticals' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 306.5% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.

Headlines about INNV stock have been trending somewhat positive on Saturday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovus Pharmaceuticals earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Innovus Pharmaceuticals.

Some companies that are related to Innovus Pharmaceuticals include Correvio Pharma (CORV), Conatus Pharmaceuticals (CNAT), Heat Biologics (HTBX), Mateon Therapeutics (MATN), Aytu Bioscience (AYTU), Novelion Therapeutics (NVLNF), IMMURON LTD/S (IMRN), Zosano Pharma (ZSAN), Novelion Therapeutics (NVLN), Nemus Bioscience (NMUS), Diffusion Pharmaceuticals (DFFN), KITOV PHARMA LT/S (KTOV), Novan (NOVN), Cyclacel Pharmaceuticals (CYCC) and OTCMKTS:EMBI (EMBI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovus Pharmaceuticals investors own include EEStor (ESU), Antares Pharma (ATRS), The Medicines (MDCO), Federal National Mortgage Association (FNMA), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), NVIDIA (NVDA), Pacific Premier Bancorp (PPBI) and Prospect Capital (PSEC).

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNV stock can currently be purchased for approximately $1.23.

Innovus Pharmaceuticals has a market capitalization of $3.94 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.

The official website for Innovus Pharmaceuticals is http://www.innovuspharma.com/.

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]